S&P 500   3,917.80 (+0.94%)
DOW   31,911.08 (+1.19%)
QQQ   321.77 (+0.09%)
AAPL   124.26 (-1.27%)
MSFT   232.83 (-0.19%)
FB   264.53 (-0.50%)
GOOGL   2,070.04 (+0.48%)
AMZN   3,151.69 (-1.34%)
TSLA   728.23 (+4.21%)
NVDA   569.60 (+0.69%)
BABA   249.83 (-1.16%)
CGC   35.59 (+0.79%)
GE   13.16 (+4.53%)
MU   90.77 (+2.88%)
NIO   51.09 (+4.03%)
AMD   85.79 (+1.24%)
T   29.36 (+0.62%)
F   12.00 (+3.27%)
ACB   11.39 (+1.61%)
DIS   199.05 (+0.99%)
BA   226.84 (+6.94%)
NFLX   550.54 (+0.80%)
BAC   36.21 (+1.94%)
S&P 500   3,917.80 (+0.94%)
DOW   31,911.08 (+1.19%)
QQQ   321.77 (+0.09%)
AAPL   124.26 (-1.27%)
MSFT   232.83 (-0.19%)
FB   264.53 (-0.50%)
GOOGL   2,070.04 (+0.48%)
AMZN   3,151.69 (-1.34%)
TSLA   728.23 (+4.21%)
NVDA   569.60 (+0.69%)
BABA   249.83 (-1.16%)
CGC   35.59 (+0.79%)
GE   13.16 (+4.53%)
MU   90.77 (+2.88%)
NIO   51.09 (+4.03%)
AMD   85.79 (+1.24%)
T   29.36 (+0.62%)
F   12.00 (+3.27%)
ACB   11.39 (+1.61%)
DIS   199.05 (+0.99%)
BA   226.84 (+6.94%)
NFLX   550.54 (+0.80%)
BAC   36.21 (+1.94%)
S&P 500   3,917.80 (+0.94%)
DOW   31,911.08 (+1.19%)
QQQ   321.77 (+0.09%)
AAPL   124.26 (-1.27%)
MSFT   232.83 (-0.19%)
FB   264.53 (-0.50%)
GOOGL   2,070.04 (+0.48%)
AMZN   3,151.69 (-1.34%)
TSLA   728.23 (+4.21%)
NVDA   569.60 (+0.69%)
BABA   249.83 (-1.16%)
CGC   35.59 (+0.79%)
GE   13.16 (+4.53%)
MU   90.77 (+2.88%)
NIO   51.09 (+4.03%)
AMD   85.79 (+1.24%)
T   29.36 (+0.62%)
F   12.00 (+3.27%)
ACB   11.39 (+1.61%)
DIS   199.05 (+0.99%)
BA   226.84 (+6.94%)
NFLX   550.54 (+0.80%)
BAC   36.21 (+1.94%)
S&P 500   3,917.80 (+0.94%)
DOW   31,911.08 (+1.19%)
QQQ   321.77 (+0.09%)
AAPL   124.26 (-1.27%)
MSFT   232.83 (-0.19%)
FB   264.53 (-0.50%)
GOOGL   2,070.04 (+0.48%)
AMZN   3,151.69 (-1.34%)
TSLA   728.23 (+4.21%)
NVDA   569.60 (+0.69%)
BABA   249.83 (-1.16%)
CGC   35.59 (+0.79%)
GE   13.16 (+4.53%)
MU   90.77 (+2.88%)
NIO   51.09 (+4.03%)
AMD   85.79 (+1.24%)
T   29.36 (+0.62%)
F   12.00 (+3.27%)
ACB   11.39 (+1.61%)
DIS   199.05 (+0.99%)
BA   226.84 (+6.94%)
NFLX   550.54 (+0.80%)
BAC   36.21 (+1.94%)
Log in
OTCMKTS:EXDI

Exactus Stock Forecast, Price & News

$0.19
-0.02 (-9.73 %)
(As of 02/23/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.17
Now: $0.19▼
$0.21
50-Day Range
$0.05
MA: $0.14▼
$0.25
52-Week Range
$0.04
Now: $0.19▼
$0.33
Volume157,850 shs
Average Volume185,397 shs
Market Capitalization$11.26 million
P/E RatioN/A
Dividend YieldN/A
Beta4.95
Exactus, Inc., is a farmer and manufacturer of hemp-derived phytocannabinoid products. The company sells its CBD products through its Green Goddess brand and third-party resellers. Exactus is engaged in producing industrial hemp from farms in Oregon and plans to extract and manufacture directly through cGMP facilities. Industrial hemp is a type of cannabis, defined by the federal government as having THC (tetrahydrocannabinol) content of 0.3 percent or less. THC is the psychoactive compound found in cannabis.

Headlines

Exactus Inc.: Exactus, Inc. Reports Third Quarter 2020 Financial Results
November 21, 2020 |  finanznachrichten.de
Exactus, Inc. Reports Third Quarter 2020 Financial Results
November 19, 2020 |  finance.yahoo.com
Exactus Inc
August 22, 2020 |  bloomberg.com
Exactus, Inc. Reports Second Quarter 2020 Financial Results and Conference Call
August 20, 2020 |  finance.yahoo.com
Exactus, Inc. Reports First Quarter 2020 Financial Results
July 1, 2020 |  finance.yahoo.com
Cannabinoid Consolidation (Podcast Transcript)
June 15, 2020 |  seekingalpha.com
Exactus, Inc. Reports 2019 Year End Results
May 26, 2020 |  finance.yahoo.com
Exactus Appoints Technology Expert Mark Alouf to Its Advisory Board
May 12, 2020 |  www.benzinga.com
Exactus Announces the Promotion of Derek Du Chesne as Company President and appointment to the Board of Directors
May 11, 2020 |  finance.yahoo.com
Exactus Appoints Co-Founder of Rokt Justin Viles to its Board of Directors
May 8, 2020 |  finance.yahoo.com
Exactus Appoints Former Broadcast Media Executive Larry Wert to Its Board of Directors
May 4, 2020 |  finance.yahoo.com
Exactus, Inc. Launches a Genetics Division to Supply Farmers with FDA Compliant Feminized CBD and CBG Hemp Seeds
April 28, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:EXDI
Previous Symbol
CUSIPN/A
CIK1552189
Webwww.exactusinc.com
Phone804-205-5036
Employees4
Year FoundedN/A

Debt

Debt-to-Equity Ratio0.30
Current Ratio0.23
Quick Ratio0.20

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$350,000.00
Price / Sales32.18
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.09 per share
Price / Book2.06

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-9,690,000.00
Net Margins-534.62%
Return on Equity-1,142.18%
Return on Assets-169.78%

Miscellaneous

Outstanding Shares60,713,000
Market Cap$11.26 million
Next Earnings Date5/25/2021 (Estimated)
OptionableNot Optionable

MarketRank™

Overall MarketRank™

0.54 out of 5 stars

Medical Sector

1439th out of 1,958 stocks

Medicinals & Botanicals Industry

19th out of 33 stocks

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$0.19
-0.02 (-9.73 %)
(As of 02/23/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EXDI News and Ratings via Email

Sign-up to receive the latest news and ratings for EXDI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Exactus (OTCMKTS:EXDI) Frequently Asked Questions

What stocks does MarketBeat like better than Exactus?

Wall Street analysts have given Exactus a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Exactus wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Exactus?

Exactus saw a increase in short interest during the month of January. As of January 29th, there was short interest totaling 9,600 shares, an increase of 9,500.0% from the January 14th total of 100 shares. Based on an average daily trading volume, of 466,300 shares, the short-interest ratio is presently 0.0 days.
View Exactus' Short Interest.

When is Exactus' next earnings date?

Exactus is scheduled to release its next quarterly earnings announcement on Tuesday, May 25th 2021.
View our earnings forecast for Exactus.

How has Exactus' stock price been impacted by Coronavirus (COVID-19)?

Exactus' stock was trading at $0.2350 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, EXDI stock has decreased by 21.1% and is now trading at $0.1855.
View which stocks have been most impacted by COVID-19.

Who are Exactus' key executives?

Exactus' management team includes the following people:
  • Emiliano Aloi, President and Interim CEO
  • Kenneth E. Puzder, Chief Financial Officer and Director
  • Andrew Johnson, Chief Strategy Officer
  • Bobby Yampolsky, Interim Chairman

Who are some of Exactus' key competitors?

Some companies that are related to Exactus include True Drinks (TRUU), FSD Pharma (HUGE), Mannatech (MTEX), Tauriga Sciences (TAUG), FitLife Brands (FTLF), Heyu Biological Technology (HYBT), Cyanotech (CYAN), GLG Life Tech (GLGLF), Entia Biosciences (ERGO), Rock Creek Pharmaceuticals (RCPIQ), Beleave (BE), Beleave (BE), ONE Bio (ONBI), PacificHealth Laboratories (PHLI) and Synovics Pharmaceuticals (SYVC).
View all of EXDI's competitors.

What other stocks do shareholders of Exactus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exactus investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), (PCSA), Akero Therapeutics (AKRO), CymaBay Therapeutics (CBAY), Cumberland Pharmaceuticals (CPIX), Entasis Therapeutics (ETTX), Evelo Biosciences (EVLO), (HGEN) and Kaleido Biosciences (KLDO).

What is Exactus' stock symbol?

Exactus trades on the OTCMKTS under the ticker symbol "EXDI."

How do I buy shares of Exactus?

Shares of EXDI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Exactus' stock price today?

One share of EXDI stock can currently be purchased for approximately $0.19.

How much money does Exactus make?

Exactus has a market capitalization of $11.26 million and generates $350,000.00 in revenue each year.

How many employees does Exactus have?

Exactus employs 4 workers across the globe.

What is Exactus' official website?

The official website for Exactus is www.exactusinc.com.

Where are Exactus' headquarters?

Exactus is headquartered at 80 NE 4th Avenue Suite 28, Delray Beach FL, 33483.

How can I contact Exactus?

Exactus' mailing address is 80 NE 4th Avenue Suite 28, Delray Beach FL, 33483. The company can be reached via phone at 804-205-5036.


This page was last updated on 2/24/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.